CORPORATE

Kedrion Biopharma will continue to market and distribute GAMMAKED in the U.S. through end of 2025

RYPLAZIM® (plasminogen, human-tvmh) will address needs in patients with ultra-rare condition Plasminogen Deficiency Type 1

KEDRAB® is now the first and only HRIG available in the U.S. to be clinically studied in children

Kedrion Biopharma Pediatric Primary Immunodeficiency Study

Kedrion Biopharma, an international biopharmaceutical company specialized in the manufacture and distribution of plasma-derived therapeutic products used in treating rare and serious diseases.

A question and answer session with the recently appointed CEO of Kedrion, Val Romberg: his first impressions of the company, his views on growth potential, and his reflections on Kedrion’s commitment to developing new anti COVID-19 therapies. 

Val Romberg from the USA, one of the most esteemed managers in the industry

Kedrion and Columbia University release video statements

The two companies are now working to expand the Clinical Development Program to the US